Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants

Mader, 2022, Omicron's binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals, iScience, 25, 10.1016/j.isci.2022.104076 Cao, 2022, Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies, Nature, 602, 657, 10.1038/s41586-021-04385-3 Takashita, 2022, Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants, N Engl J Med, 387, 468, 10.1056/NEJMc2207519 Piccicacco, 2022, Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge, J Antimicrob Chemother, 77, 2693, 10.1093/jac/dkac256 Wu, 2020, A new coronavirus associated with human respiratory disease in China, Nature, 579, 265, 10.1038/s41586-020-2008-3 Yang, 2021, Structural basis of a human neutralizing antibody specific to the SARS-CoV-2 spike protein receptor-binding domain, Microbiol Spectr, 9, 10.1128/Spectrum.01352-21 Hu, 2017, Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus, PLoS Pathog, 13, 10.1371/journal.ppat.1006698 Gorbalenya, 2020, The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nat Microbiol, 5, 536, 10.1038/s41564-020-0695-z Shang, 2020, The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines, NPJ Vaccines, 5, 18, 10.1038/s41541-020-0170-0 Hulswit, 2016, Coronavirus spike protein and tropism changes, Adv Virus Res, 96, 29, 10.1016/bs.aivir.2016.08.004 Belouzard, 2012, Mechanisms of coronavirus cell entry mediated by the viral spike protein, Viruses, 4, 1011, 10.3390/v4061011 Najjar Debbiny, 2023, Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients, Clin Infect Dis, 76, e342, 10.1093/cid/ciac443 U.S. Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for paxlovidtm. Available from: https://www.fda.gov/media/155050/download. Najjar-Debbiny, 2023, Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients, Clin Infect Dis, 76, e342, 10.1093/cid/ciac443 Lamb, 2020, Remdesivir: First Approval, Drugs, 80, 1355, 10.1007/s40265-020-01378-w Cox, 2023, SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies, Nat Rev Micro, 21, 112, 10.1038/s41579-022-00809-7 Jacobs, 2023, COVID-19: Challenges of viral variants, Annu Rev Med, 74, 31, 10.1146/annurev-med-042921-020956 Hentzien, 2022, A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab, Lancet Infect Dis, 22, 1278, 10.1016/S1473-3099(22)00495-9 U. S. Food & Drug Administration. Frequently asked questions on the emergency use authorization for actemra (Tocilizumab) for treatment of COVID-19. Available from: https://www.fda.gov/media/150345/download. Zhou, 2023, Potent therapeutic strategies for COVID-19 with single-domain antibody immunoliposomes neutralizing SARS-CoV-2 and lip/cGAMP enhancing protective immunity, Int J Mol Sci, 24, 4068, 10.3390/ijms24044068 Ramana, 2015, Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs – modern Trojan horses to combat HIV, Eur J Pharm Biopharm, 89, 300, 10.1016/j.ejpb.2014.11.021 Rani, 2022, Surface-engineered liposomes for dual-drug delivery targeting strategy against methicillin-resistant Staphylococcus aureus (MRSA), Asian J Pharm Sci, 17, 102, 10.1016/j.ajps.2021.11.004 Mat Rani, 2021, Exploring the possible targeting strategies of liposomes against methicillin-resistant Staphylococcus aureus (MRSA), Eur J Pharm Biopharm, 165, 84, 10.1016/j.ejpb.2021.04.021 Dini Fatini Mohammad Faizal, 2023, Recent updates on liposomal formulations for detection, prevention and treatment of coronavirus disease (COVID-19), Int J Pharm, 630, 10.1016/j.ijpharm.2022.122421 Kheoane, 2023, Formulation and characterization of liposomes containing drug absorption enhancers for optimized anti-HIV and antimalarial drug delivery, Drug Deliv Transl Res, 13, 1358, 10.1007/s13346-022-01264-w Idris, 2021, A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19, Mol Ther, 29, 2219, 10.1016/j.ymthe.2021.05.004 Wang, 2022, MPLA-adjuvanted liposomes encapsulating S-trimer or RBD or S1, but not S-ECD, elicit robust neutralization against SARS-CoV-2 and variants of concern, J Med Chem, 65, 3563, 10.1021/acs.jmedchem.1c02025 Mabrouk, 2021, Lyophilized, thermostable Spike or RBD immunogenic liposomes induce protective immunity against SARS-CoV-2 in mice, Sci Adv, 7, eabj1476, 10.1126/sciadv.abj1476 Suk, 2016, PEGylation as a strategy for improving nanoparticle-based drug and gene delivery, Adv Drug Deliv Rev, 99, 28, 10.1016/j.addr.2015.09.012 Voronovic, 2021, Uptake of upconverting nanoparticles by breast cancer cells: Surface coating versus the protein corona, ACS Appl Mater Interfaces, 13, 39076, 10.1021/acsami.1c10618 Zylberberg, 2016, Pharmaceutical liposomal drug delivery: A review of new delivery systems and a look at the regulatory landscape, Drug Deliv, 23, 3319, 10.1080/10717544.2016.1177136 Khantasup, 2014, Targeted small interfering RNA-immunoliposomes as a promising therapeutic agent against highly pathogenic avian influenza A (H5N1) virus infection, Antimicrob Agents Chemother, 58, 2816, 10.1128/AAC.02768-13 Clayton, 2009, Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes, Antiviral Res, 84, 142, 10.1016/j.antiviral.2009.08.003 Gramatica, 2014, αEnv-decorated phosphatidylserine liposomes trigger phagocytosis of HIV-virus-like particles in macrophages, Nanomedicine, 10, e981, 10.1016/j.nano.2014.02.008 Falco, 2013, Melittin-loaded immunoliposomes against viral surface proteins, a new approach to antiviral therapy, Antiviral Res, 97, 218, 10.1016/j.antiviral.2012.12.004 Eloy, 2017, Immunoliposomes: A review on functionalization strategies and targets for drug delivery, Colloids Surf B Biointerfaces, 159, 454, 10.1016/j.colsurfb.2017.07.085 Riaz, 2018, Surface functionalization and targeting strategies of liposomes in solid tumor therapy: A review, Int J Mol Sci, 19, 195, 10.3390/ijms19010195 Montazersaheb, 2022, COVID-19 infection: An overview on cytokine storm and related interventions, Virol J, 19, 92, 10.1186/s12985-022-01814-1 Park, 2020, Macrophages: a Trojan horse in COVID-19?, Nat Rev Immunol, 20, 351, 10.1038/s41577-020-0317-2 Zheng, 2022, Mechanism of COVID-19 causing ARDS: Exploring the possibility of preventing and treating SARS-CoV-2, Front Cell Infect Microbiol, 12, 10.3389/fcimb.2022.931061 Yang, 2020, Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor, Nat Commun, 11, 4541, 10.1038/s41467-020-18319-6 Arisoy, 2022, Development of ACE2 loaded decoy liposomes and their effect on SARS-CoV-2 for COVID-19 treatment, Pharm Dev Technol, 27, 290, 10.1080/10837450.2022.2042557 Naqvi, 2020, Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach, Biochimica et Biophysica Acta (BBA) - Mol Basis Dis, 1866 Satta, 2022, An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages, Theranostics, 12, 2639, 10.7150/thno.66831 Gibson, 2020, COVID-19 acute respiratory distress syndrome (ARDS): Clinical features and differences from typical pre-COVID-19 ARDS, Med J Aust, 213, 54, 10.5694/mja2.50674 Haque, 2021, Site-selective lysine conjugation methods and applications towards antibody-drug conjugates, Chem Commun (Camb), 57, 10689, 10.1039/D1CC03976H Xiao, 2018, Vinorelbine cationic liposomes modified with wheat germ agglutinin for inhibiting tumor metastasis in treatment of brain glioma, Artif Cells Nanomed Biotechnol, 46, 524, 10.1080/21691401.2018.1501377 Zhang, 2019, Holo-lactoferrin modified liposome for relieving tumor hypoxia and enhancing radiochemotherapy of cancer, Small, 15 Zhao, 2020, Lactoferrin-mediated macrophage targeting delivery and patchouli alcohol-based therapeutic strategy for inflammatory bowel diseases, Acta Pharm Sin B, 10, 1966, 10.1016/j.apsb.2020.07.019 Hama, 2021, Rapid modification of antibodies on the surface of liposomes composed of high-affinity protein A-conjugated phospholipid for selective drug delivery, Biochem Biophys Rep, 27 Singh, 2022, Functionalized bosutinib liposomes for target specific delivery in management of estrogen-positive cancer, Colloids Surf B Biointerfaces, 218, 10.1016/j.colsurfb.2022.112763 Lian, 2021, Galactose modified liposomes for effective co-delivery of doxorubicin and combretastatin A4, Int J Nanomedicine, 16, 457, 10.2147/IJN.S283793 Damm, 2022, Covalent coupling of HIV-1 glycoprotein trimers to biodegradable calcium phosphate nanoparticles via genetically encoded aldehyde-tags, Acta Biomater, 140, 586, 10.1016/j.actbio.2021.12.022 Ringe, 2020, Neutralizing antibody induction by HIV-1 envelope glycoprotein SOSIP trimers on iron oxide nanoparticles may be impaired by mannose binding lectin, J Virol, 94, 6, 10.1128/JVI.01883-19 Shao, 2021, Rapid detection of SARS-CoV-2 antigens using high-purity semiconducting single-walled carbon nanotube-based field-effect transistors, ACS Appl Mater Interfaces, 13, 10321, 10.1021/acsami.0c22589 Zamzami, 2022, Carbon nanotube field-effect transistor (CNT-FET)-based biosensor for rapid detection of SARS-CoV-2 (COVID-19) surface spike protein S1, Bioelectrochemistry, 143, 10.1016/j.bioelechem.2021.107982 Gai, 2020, A bio-orthogonal functionalization strategy for site-specific coupling of antibodies on vesicle surfaces after self-assembly, Polym Chem, 11, 527, 10.1039/C9PY01136F Witte, 2015, Site-specific protein modification using immobilized sortase in batch and continuous-flow systems, Nat Protoc, 10, 508, 10.1038/nprot.2015.026 Pishesha, 2018, Sortase A: A model for transpeptidation and its biological applications, Annu Rev Cell Dev Biol, 34, 163, 10.1146/annurev-cellbio-100617-062527 Lupoli, 2011, Transpeptidase-mediated incorporation of amino acids into bacterial peptidoglycan, J Am Chem Soc, 133, 10748, 10.1021/ja2040656 Mao, 2004, Sortase-mediated protein ligation: A new method for protein engineering, J Am Chem Soc, 126, 2670, 10.1021/ja039915e Reed, 2020, Efficient sortase-mediated ligation using a common C-terminal fusion tag, Bioconjug Chem, 31, 1463, 10.1021/acs.bioconjchem.0c00156 Fottner, 2019, Site-specific ubiquitylation and SUMOylation using genetic-code expansion and sortase, Nat Chem Biol, 15, 276, 10.1038/s41589-019-0227-4 Ge, 2019, Enzyme-mediated intercellular proximity labeling for detecting cell–cell interactions, J Am Chem Soc, 141, 1833, 10.1021/jacs.8b10286 Shadish, 2019, Bioactive site-specifically modified proteins for 4D patterning of gel biomaterials, Nat Mater, 18, 1005, 10.1038/s41563-019-0367-7 Singh, 2019, Sortase-click strategy for defined protein conjugation on a heptavalent cyclodextrin scaffold, PLoS One, 14, 10.1371/journal.pone.0217369 Hebbrecht, 2020, Nanobody click chemistry for convenient site-specific fluorescent labelling, single step immunocytochemistry and delivery into living cells by photoporation and live cell imaging, N Biotechnol, 59, 33, 10.1016/j.nbt.2020.05.004 Silvius, 2017, A novel “prebinding” strategy dramatically enhances sortase-mediated coupling of proteins to liposomes, Bioconjug Chem, 28, 1271, 10.1021/acs.bioconjchem.7b00087 Takahara, 2020, Synthetic strategies for artificial lipidation of functional proteins, Chemistry – A Eur J, 26, 4645, 10.1002/chem.201904568 Wu, 2012, Sortase-mediated transpeptidation for site-specific modification of peptides, glycopeptides, and proteins, J Carbohydr Chem, 31, 48, 10.1080/07328303.2011.635251 Wöll, 2018, Sortaggable liposomes: evaluation of reaction conditions for single-domain antibody conjugation by Sortase-A and targeting of CD11b+ myeloid cells, Eur J Pharm Biopharm, 133, 138, 10.1016/j.ejpb.2018.09.017 Wöll, 2019, Sortagging of liposomes with a murine CD11b-specific VHH increases in vitro and in vivo targeting specificity of myeloid cells, Eur J Pharm Biopharm, 134, 190, 10.1016/j.ejpb.2018.11.014 Bai, 2021, Facile Generation of potent bispecific fab via sortase A and click chemistry for cancer immunotherapy, Cancers (Basel), 13, 4540, 10.3390/cancers13184540 van Moorsel, 2019, A head-to-head comparison of conjugation methods for VHHs: Random maleimide-thiol coupling versus controlled click chemistry, Int J Pharm X, 1 Witte, 2013, Production of unnaturally linked chimeric proteins using a combination of sortase-catalyzed transpeptidation and click chemistry, Nat Protoc, 8, 1808, 10.1038/nprot.2013.103 Jendryczko, 2022, Drug conjugation via maleimide–thiol chemistry does not affect targeting properties of cysteine-containing anti-FGFR1 peptibodies, Mol Pharm, 19, 1422, 10.1021/acs.molpharmaceut.1c00946 Huwyler, 1996, Brain drug delivery of small molecules using immunoliposomes, P Natl Acad Sci USA, 93, 14164, 10.1073/pnas.93.24.14164 Yang, 2007, Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome, J Controlled Release, 120, 169, 10.1016/j.jconrel.2007.05.011 Rodallec, 2020, Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3), Anticancer Drugs, 31, 463, 10.1097/CAD.0000000000000878 Rodallec, 2018, From 3D spheroids to tumor bearing mice: Efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer, Int J Nanomedicine, 13, 6677, 10.2147/IJN.S179290 Whittenton, 2013, Evaluation of asymmetric immunoliposomal nanoparticles for cellular uptake, J Microencapsul, 30, 55, 10.3109/02652048.2012.696152 Kim, 2004, Immunoliposomes carrying plasmid DNA: Preparation and characterization, Arch Pharm Res, 27, 1263, 10.1007/BF02975892 Arslan, 2021, Antibody-mediated drug delivery, Int J Pharm, 596, 12028, 10.1016/j.ijpharm.2021.120268 Scaria, 2017, Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity, PLoS One, 12, 10.1371/journal.pone.0190312 Cammarata, 2015, Carbodiimide induced cross-linking, ligand addition, and degradation in gelatin, Mol Pharm, 12, 783, 10.1021/mp5006118 Adeagbo, 2020, Controlled covalent conjugation of a tuberculosis subunit antigen (ID93) to liposome improved in vitro Th1-type cytokine recall responses in human whole blood, ACS Omega, 5, 31306, 10.1021/acsomega.0c04774 Manjappa, 2011, Antibody derivatization and conjugation strategies: Application in preparation of stealth immunoliposome to target chemotherapeutics to tumor, J Controlled Release, 150, 2, 10.1016/j.jconrel.2010.11.002 Raju, 2013, Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel, Expert Opin Drug Deliv, 10, 747, 10.1517/17425247.2013.777425 Park, 2008, Non-labeled detection of waterborne pathogen Cryptosporidium parvum using a polydiacetylene-based fluorescence chip, Biotechnol J, 3, 687, 10.1002/biot.200700246 Lin, 2017, Dopamine-loaded liposomes for in-situ amplified photoelectrochemical immunoassay of AFB1 to enhance photocurrent of Mn2+-doped Zn3(OH)2V2O7, Nanobelts Anal Chem, 89, 11803, 10.1021/acs.analchem.7b03451 Thorek, 2009, Comparative analysis of nanoparticle-antibody conjugations: carbodiimide versus click chemistry, Mol Imaging, 8, 7290, 10.2310/7290.2009.00021 Neurath, 2008, Immune response to viruses: antibody-mediated immunity, 56 Wrapp, 2020, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science (1979), 367, 1260 Chen, 2023, Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses, Nat Rev Immunol, 23, 189, 10.1038/s41577-022-00784-3 Jiang, 2021, Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV, MAbs, 13, 10.1080/19420862.2021.1953683 Hanke, 2020, An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction, Nat Commun, 11, 4420, 10.1038/s41467-020-18174-5 Zhou, 2019, Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding Domain, Viruses, 11, 60, 10.3390/v11010060 Jiang, 2020, Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses, Trends Immunol, 41, 545, 10.1016/j.it.2020.04.008